[1]
|
Qiu, Z., Oleinick, N.L. and Zhang, J. (2018) ATR/CHK1 Inhibitors and Cancer Therapy. Radiotherapy & Oncology, 126, 450-464. https://doi.org/10.1016/j.radonc.2017.09.043
|
[2]
|
Jackson, S.P. and Bartek, J. (2009) TheDNA-Damage Response in Human Biology and Disease. Nature, 461, 1071-1078.
https://doi.org/10.1038/nature08467
|
[3]
|
Marchal, A. and Zou, L. (2013) DNA Damage Sensing by the ATM and ATRkinase. Cold Spring Harbor Perspectives in Biology, 5, Article ID: a012716. https://doi.org/10.1101/cshperspect.a012716
|
[4]
|
Shiotani, B. and Zou, L. (2009) ATR Signaling at a Glance. Journal of Cell Science, 122, 301-304.
https://doi.org/10.1242/jcs.035105
|
[5]
|
Enriquez-Rios, V., Dumitrache, L.C., Downing, S.M., et al. (2017) DNA-PKcs, ATM, and ATR Interplay Maintains Genome Integrity during Neu-Rogenesis. Journal of Neuroscience, 37, 893-905.
https://doi.org/10.1523/JNEUROSCI.4213-15.2016
|
[6]
|
Foote, K.M, Lau, A. and Nissink, JW. (2015) Drugging ATR: Progress in the Development of Specific Inhibitors for the Treatment of Cancer. Future Medicinal Chemistry, 7, 873-891. https://doi.org/10.4155/fmc.15.33
|
[7]
|
Weber, A.M. and Ryan, A.J. (2015) ATM and ATR as Thera-peutic Targets in Cancer. Pharmacology & Therapeutics, 149, 124-138. https://doi.org/10.1016/j.pharmthera.2014.12.001
|
[8]
|
Murga, M., Bunting, S., Montana, M.F., et al. (2009) A Mouse Model of ATR-Seckel Shows Embryonic Replicative Stress and Accelerated Aging. Nature Genetics, 41, 891-898. https://doi.org/10.1038/ng.420
|
[9]
|
Dillon, M.T., Barker, H.E., Pedersen, M., et al. (2017) Radiosensiti-zation by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. Molecular Cancer Therapeutics, 16, 25-34.
https://doi.org/10.1158/1535-7163.MCT-16-0239
|
[10]
|
Reaper, P.M., Griffiths, M.R., Long, J.M., et al. (2011) Selective Killing of ATM- or p53-Deficient Cancer Cells through Inhibition of ATR. Nature Chemical Biology, 7, 428-430. https://doi.org/10.1038/nchembio.573
|
[11]
|
Middleton, F.K., Pollard, J.R. and Curtin, N.J. (2018) The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation. Cancers, 10, Article No. 275. https://doi.org/10.3390/cancers10080275
|
[12]
|
Barsanti, P.A., Pan, Y., Lu, Y., et al. (2015) Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors. ACS Medicinal Chemistry Letter, 6, 42-46. https://doi.org/10.1021/ml500352s
|
[13]
|
Kwok, M., Davies, N., Agathanggelou, A., et al. (2016) ATR Inhibition Induces Synthetic Lethality and Overcomes Chemoresistance in TP53 or ATM-Defective Chronic Lym-phocytic Leukemia Cells. Blood, 127, 582-595.
https://doi.org/10.1182/blood-2015-05-644872
|
[14]
|
Peasland, A., Wang, L.Z., Rowling, E., et al. (2011) Identifi-cation and Evaluation of a Potent Novel ATR Inhibitor, NU6027, in Breast and Ovarian Cancer Cell Lines. British Jour-nal of Cancer, 105, 372-381.
https://doi.org/10.1038/bjc.2011.243
|
[15]
|
Fokas, E., Prevo, R., Pollard, J.R., et al. (2012) Targeting ATR in Vivo Using the Novel Inhibitor VE-822 Results in Selective Sensitization of Pancreatic Tumors to Radiation. Cell Death & Diseases, 3, Article No. e441.
https://doi.org/10.1038/cddis.2012.181
|
[16]
|
Ramachandran, S.A., Jadhavar, P.S., Singh, M.P., et al. (2017) Dis-covery of Pyrazolopyrimidine Derivatives as Novel Inhibitors of Ataxia Telangiectasia and Rad3 Related Protein (ATR). Bioorganic & Medicinal Chemistry Letters, 27, 750-754. https://doi.org/10.1016/j.bmcl.2017.01.045
|
[17]
|
Charrier, J.D., Durrant, S.J., Golec, J.M., et al. (2011) Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mu-tated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents. Journal of Medicinal Chemistry, 54, 2320-2330. https://doi.org/10.1021/jm101488z
|
[18]
|
Petermann, E. and Caldecott, K.W. (2006) Evidence That the ATR/Chk1 Pathway Maintains Normal Replication Fork Progression during Unperturbed S Phase. Cell Cycle, 5, 2203-2209.
|
[19]
|
Knegtel, R., Charrier, J.D., Durrant, S., Davis, C., O’Donnell, M., Storck, P., MacCormick, S., et al. (2019) Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor. Journal of Medicinal Chemistry, 62, 5547-5561.
https://doi.org/10.1021/acs.jmedchem.9b00426
|
[20]
|
Karanika, S., Karantanos, T., Li, L., et al. (2015) DNA Dam-age Response and Prostate Cancer: Defects Regulation and Therapeutic Implications. Oncogene, 34, 2815-2822. https://doi.org/10.1038/onc.2014.238
|
[21]
|
Cossar, L., Schache, A., Risk, J., et al. (2017) Modulating the DNA Damage Response to Improve Treatment Response in Cervical Cancer. Clinical Oncology, 29, 626-634. https://doi.org/10.1016/j.clon.2017.03.002
|
[22]
|
Foote, K.M., Blades, K., Cronin, A., Fillery S, Guichard, S.S., Hassall, L., Hickson, I., et al. (2013) Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl) cyclo-propyl] pyrimidin-2-yl-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in vivo Antitumor Activity. Journal of Medicinal Chemistry, 56, 2125-2138. https://doi.org/10.1021/jm301859s
|
[23]
|
Sangster-Guity, N., Conrad, B.H., Papadopoulos, N., et al. (2011) ATR Mediates Cisplatin Resistance in a p53 Genotype-Specific Manner. Oncogene, 30, 2526-2533. https://doi.org/10.1038/onc.2010.624
|
[24]
|
Chen, T., Middleton, F.K., Falcon, S., et al. (2015) Development of Pharmacodynamic Biomarkers for ATR Inhibitors. Molecular Oncology, 9, 463-472. https://doi.org/10.1016/j.molonc.2014.09.012
|
[25]
|
Chen, H., Lisby, M. and Symington, L.S. (2013) RPA Coordi-nates DNA End Resection and Prevents Formation of DNA Hairpins. Molecular Cell, 50, 589-600. https://doi.org/10.1016/j.molcel.2013.04.032
|
[26]
|
Liu, Q., Kirubakaran, S., Hur, W., et al. (2012) Kinome-Wide Selectivity Profiling of ATP-Competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. Journal of Biological Chemistry, 287, 9742-9752. https://doi.org/10.1074/jbc.M111.304485
|
[27]
|
Liu, Q., Xu, C., Kirubakaran, S., et al. (2013) Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR. Cancer Research, 73, 2574-2586. https://doi.org/10.1158/0008-5472.CAN-12-1702
|
[28]
|
Toledo, L.I., Murga, M., Fernandez-Capetillo, O. (2011) Targeting ATR and Chk1 Kinases for Cancer Treatment: A New Model for New (and Old) Drugs. Molecular Oncology, 5, 368-373. https://doi.org/10.1016/j.molonc.2011.07.002
|
[29]
|
Foote, K.M., Nissink, J.W.M., Mcguire, T., et al. (2018) Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Re-lated (ATR) Kinase with Application as an Anticancer Agent. Journal of Medicinal Chemistry, 61, 9889-9907. https://doi.org/10.1021/acs.jmedchem.8b01187
|
[30]
|
Do, K. and Chen, A.P. (2013) Molecular Pathways: Targeting PARP in Cancer Treatment. Clinical Cancer Research, 19, 977-984.
|
[31]
|
Gaudio, E., Tarantelli, C., Spriano, F., et al. (2019) Abstract 274: The ATR inhibitor BAY 1895344 Shows Strong Preclinical Activity in Lymphomas and Appears Associated with Specific Gene Expression Signatures. Cancer Research, 79, 2740. https://doi.org/10.1158/1538-7445.AM2019-274
|
[32]
|
Cepeda, V., Fuertes, M.A., Castilla, J., et al. (2006) Poly(ADP-Ribose)Polymerase-1(PARP-1) Inhibitors in Cancer Chemotherapy. Recent Patents on Anti-Cancer Drug Discovery, 1, 39-53.
|
[33]
|
Sarkaria, J.N., Busby, E.C., Tibbetts, R.S., et al. (1999) Inhibition of ATM and ATR Kinase Activities by the Radiosensitizing Agent, Caffeine. Cancer Research, 59, 4375-4382.
|
[34]
|
Nishida, H., Tatewaki, N., Nakajima, Y., et al. (2009) Inhibition of ATR Protein Kinase Activity by Schisandrin B in DNA Damage Response. Nu-cleic Acids Research, 37, 5678-5689. https://doi.org/10.1093/nar/gkp593
|
[35]
|
Peasland, A., Wang, L.Z., Rowling, E., et al. (2011) Identification and Evaluation of a Potent Novel ATR Inhibitor, NU6027, in Breast and Ovarian Cancer Cell Lines. British Journal of Cancer, 105, 372-381.
|
[36]
|
Barsanti, P.A., Aversa, R.J., Jin, X., et al. (2015) Struc-ture-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo [1,5-a]pyrazines as ATR Inhibitors. ACS Medicinal Chemistry Letters, 6, 37-41.
https://doi.org/10.1021/ml500353p
|
[37]
|
Combes, E., Andrade, A.F., Tosi, D., et al. (2019) Inhibition of Atax-ia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immun-ity in Colorectal Cancer. Cancer Research, 79, 2933-2946. https://doi.org/10.1158/0008-5472.CAN-18-2807
|
[38]
|
Bradbury, A., Hall, S., Curtin, N., et al. (2020) Targeting ATR as Cancer Therapy: A New Era for Synthetic Lethality and Synergistic Combinations? Pharmacology & Therapeu-tics, 207, Article ID: 107450.
https://doi.org/10.1016/j.pharmthera.2019.107450
|
[39]
|
Wallez, Y., Dunlop, C.R., Johnson, T.I., et al. (2018) The ATR Inhibitor AZD6738 Synergizes with Gemcitabine in Vitro and in Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. Molecular Cancer Therapeutics, 17, 1670-1682. https://doi.org/10.1158/1535-7163.MCT-18-0010
|
[40]
|
Lecona, E. and Fernandez-Capetillo, O. (2018) Targeting ATR in Cancer. Nature Reviews Cancer, 18, 586-595.
https://doi.org/10.1038/s41568-018-0034-3
|
[41]
|
Vendetti, F.P., Leibowitz, B.J., Barnes, J., et al. (2017) Pharma-cologic ATM But Not ATR Kinase Inhibition Abrogates p21-Dependent G1 Arrest and Promotes Gastrointestinal Syn-drome after Total Body Irradiation. Scientific Reports, 7, Article No. 41892. https://doi.org/10.1038/srep41892
|
[42]
|
Sarkaria, J.N., Tibbetts, R.S., Busby, E.C, et al. (1998) Inhibition of Phosphoinositide 3-Kinase Related Kinases by the Radio Sensitizing Agent Wortmannin. Cancer Research, 58, 4375-4382.
|
[43]
|
Grara, X., Luca, A.D., Sang, N., et al. (1994) PITALRE, a Nuclear CDC2-Related Protein Kinase That Phosphorylates the Retinoblastoma Protein in Vitro. Proceedings of the National Academy of Sciences of the United States of America, 91, 3834-3838. https://doi.org/10.1073/pnas.91.9.3834
|
[44]
|
Couch, F.B., Bansbach, C.E., Driscoll, R., et al. (2013) ATR Phosphorylates SMARCAL1 to Prevent Replication Fork Collapse. Genes & Develop-ment, 27, 1610-1623. https://doi.org/10.1101/gad.214080.113
|
[45]
|
Pleschke, J.M., Kleczkowska, H.E., Strohm, M., et al. (2000) Poly(ADP-Ribose)Binds to Specific Domains in DNA Damage Checkpoint Proteins. Journal of Bio-logical Chemistry, 275, 40974-40980.
|
[46]
|
Deng, S.K., Yin, Y, Petes, T.D., et al. (2015) Mre11-Sae2 and RPA Col-laborate to Prevent Palindromic Gene Amplification. Molecular Cell, 60, 500-508. https://doi.org/10.1016/j.molcel.2015.09.027
|